Inovio Pharmaceuticals (NASDAQ:INO) Share Price Breaks Above 200-Day Moving Average - Should You Sell?

Key Points

• Inovio shares briefly moved above their 200-day moving average of $1.21, but last traded at $1.17; the stock has a $120.98 million market capitalization and remains unprofitable.
• Analyst sentiment is generally favorable, with a “Moderate Buy” consensus and an average price target of $3.17; recent upgrades included Jefferies to positive with a $3.00 target and Zacks Research to strong buy.
• Inovio beat quarterly earnings expectations, reporting a loss of $0.07 per share versus the projected $0.22 loss, while institutional investors own approximately 26.79% of the stock.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $1.21 and traded as high as $1.21. Inovio Pharmaceuticals shares last traded at $1.17, with a volume of 1,832,781 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages recently commented on INO. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a "hold" rating to a "positive" rating and lifted their target price for the stock from $1.80 to $3.00 in a research note on Thursday, August 13th. Wall Street Zen raised shares of Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Zacks Research raised shares of Inovio Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, August 12th. HC Wainwright restated a "neutral" rating on shares of Inovio Pharmaceuticals in a research report on Thursday, August 13th. Finally, Piper Sandler restated an "overweight" rating and issued a $4.00 price objective on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Inovio Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $3.17.

Inovio Pharmaceuticals Stock Down 0.8%

The company's fifty day simple moving average is $1.11 and its 200 day simple moving average is $1.21. The firm has a market capitalization of $120.98 million, a PE ratio of -1.29 and a beta of 1.63.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. Equities research analysts forecast that Inovio Pharmaceuticals, Inc. will post -0.72 EPS for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Eversept Partners LP bought a new position in Inovio Pharmaceuticals in the first quarter worth $1,802,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Inovio Pharmaceuticals by 1,929.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 46,536 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $37,000. Squarepoint Ops LLC grew its position in shares of Inovio Pharmaceuticals by 46.5% in the 2nd quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 11,554 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter worth about $33,000. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines designed to treat and prevent serious diseases. Its platform uses synthetic DNA plasmids to instruct cells to produce targeted proteins, with delivery supported by its CELLECTRA electroporation devices. The company's research has included candidates for cancer, infectious diseases and human papillomavirus (HPV)-related conditions.

Inovio's pipeline has included INO-3107, an investigational DNA immunotherapy for recurrent respiratory papillomatosis, a rare disease caused by HPV, as well as other development programs targeting cancers and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.